Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Treatment with the dipeptidyl peptidase-4 inhibitor linagliptin or placebo followed by glimepiride in patients with type 2 diabetes with moderate to severe renal impairment: a 52-week, randomized, double-blind clinical trial.

× No keyword cloud information.

22 in total

Review 1. Molecular and clinical roles of incretin-based drugs in patients with heart failure.

Authors: Bassant Orabi; Rasha Kaddoura; Amr S Omar; Cornelia Carr; Abdulaziz Alkhulaifi
Journal: Heart Fail Rev Date: 2018-05 Impact factor: 4.214

Review 2. Intensifying Treatment Beyond Monotherapy in Type 2 Diabetes Mellitus: Where Do Newer Therapies Fit?

Authors: Alexander Kuhn; Jean Park; Adline Ghazi; Vanita R Aroda
Journal: Curr Cardiol Rep Date: 2017-03 Impact factor: 2.931

Review 3. Management of patients with type 2 diabetes and mild/moderate renal impairment: profile of linagliptin.

Authors: Baptist Gallwitz
Journal: Ther Clin Risk Manag Date: 2015-05-14 Impact factor: 2.423

4. Linagliptin and its effects on hyperglycaemia and albuminuria in patients with type 2 diabetes and renal dysfunction: the randomized MARLINA-T2D trial.

Authors: Per-Henrik Groop; Mark E Cooper; Vlado Perkovic; Berthold Hocher; Keizo Kanasaki; Masakazu Haneda; Guntram Schernthaner; Kumar Sharma; Robert C Stanton; Robert Toto; Jessica Cescutti; Maud Gordat; Thomas Meinicke; Audrey Koitka-Weber; Sandra Thiemann; Maximilian von Eynatten
Journal: Diabetes Obes Metab Date: 2017-07-31 Impact factor: 6.577

5. Cardiovascular Outcomes Comparison of Dipeptidyl Peptidase-4 Inhibitors versus Sulfonylurea as Add-on Therapy for Type 2 Diabetes Mellitus: a Meta-Analysis.

Authors: Won Kyeong Jeon; Jeehoon Kang; Hyo-Soo Kim; Kyung Woo Park
Journal: J Lipid Atheroscler Date: 2021-01-25

Review 6. Insulin and glucose-lowering agents for treating people with diabetes and chronic kidney disease.

Authors: Clement Lo; Tadashi Toyama; Ying Wang; Jin Lin; Yoichiro Hirakawa; Min Jun; Alan Cass; Carmel M Hawley; Helen Pilmore; Sunil V Badve; Vlado Perkovic; Sophia Zoungas
Journal: Cochrane Database Syst Rev Date: 2018-09-24

Review 7. Dipeptidyl peptidase-4 inhibitors and risk of heart failure in type 2 diabetes: systematic review and meta-analysis of randomised and observational studies.

Authors: Ling Li; Sheyu Li; Ke Deng; Jiali Liu; Per Olav Vandvik; Pujing Zhao; Longhao Zhang; Jiantong Shen; Malgorzata M Bala; Zahra N Sohani; Evelyn Wong; Jason W Busse; Shanil Ebrahim; German Malaga; Lorena P Rios; Yingqiang Wang; Qunfei Chen; Gordon H Guyatt; Xin Sun
Journal: BMJ Date: 2016-02-17

8. An updated systematic review and meta-analysis on the efficacy and tolerability of dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes with moderate to severe chronic kidney disease.

Authors: Devada Singh-Franco; Catherine Harrington; Eglis Tellez-Corrales
Journal: SAGE Open Med Date: 2016-07-28

Review 9. Systematic Literature Review of DPP-4 Inhibitors in Patients with Type 2 Diabetes Mellitus and Renal Impairment.

Authors: Merlin C Thomas; Päivi M Paldánius; Rajeev Ayyagari; Siew Hwa Ong; Per-Henrik Groop
Journal: Diabetes Ther Date: 2016-08-08 Impact factor: 2.945

10. Effects and Safety of Linagliptin as an Add-on Therapy in Advanced-Stage Diabetic Nephropathy Patients Taking Renin-Angiotensin-Aldosterone System Blockers.

Authors: Yuichiro Ueda; Hiroki Ishii; Taisuke Kitano; Mitsutoshi Shindo; Haruhisa Miyazawa; Kiyonori Ito; Keiji Hirai; Yoshio Kaku; Honami Mori; Taro Hoshino; Susumu Ookawara; Masafumi Kakei; Kaoru Tabei; Yoshiyuki Morishita
Journal: Drug Target Insights Date: 2016-09-11